Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 445

1.

68Ga-exendin-4 PET/CT detects insulinomas in patients with endogenous hyperinsulinemic hypoglycemia in MEN-1.

Antwi K, Nicolas G, Fani M, Heye T, Pattou F, Grossman A, Chanson P, Reubi JC, Aurrel P, Gloor B, Vogt DR, Wild D, Christ E.

J Clin Endocrinol Metab. 2019 Jul 12. pii: jc.2018-02754. doi: 10.1210/jc.2018-02754. [Epub ahead of print]

PMID:
31298706
2.

Localization of 99mTc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses.

Kaloudi A, Lymperis E, Kanellopoulos P, Waser B, de Jong M, Krenning EP, Reubi JC, Nock BA, Maina T.

Pharmaceuticals (Basel). 2019 Mar 20;12(1). pii: E42. doi: 10.3390/ph12010042.

3.

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients.

Daly A, Rostomyan L, Betea D, Bonneville JF, Villa C, Pellegata NS, Waser B, Reubi JC, Waeber Stephan C, Christ E, Beckers A.

Endocr Connect. 2019 Mar 1. pii: EC-19-0004.R1. doi: 10.1530/EC-19-0004. [Epub ahead of print]

4.

The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist.

Abiraj K, Ursillo S, Tamma ML, Rylova SN, Waser B, Constable EC, Fani M, Nicolas GP, Reubi JC, Maecke HR.

EJNMMI Res. 2018 Aug 2;8(1):75. doi: 10.1186/s13550-018-0428-y.

5.

New Gastrin Releasing Peptide Receptor-Directed [99mTc]Demobesin 1 Mimics: Synthesis and Comparative Evaluation.

Nock BA, Charalambidis D, Sallegger W, Waser B, Mansi R, Nicolas GP, Ketani E, Nikolopoulou A, Fani M, Reubi JC, Maina T.

J Med Chem. 2018 Apr 12;61(7):3138-3150. doi: 10.1021/acs.jmedchem.8b00177. Epub 2018 Mar 19.

PMID:
29517903
6.

Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study.

Nicolas GP, Beykan S, Bouterfa H, Kaufmann J, Bauman A, Lassmann M, Reubi JC, Rivier JEF, Maecke HR, Fani M, Wild D.

J Nucl Med. 2018 Jun;59(6):909-914. doi: 10.2967/jnumed.117.199737. Epub 2017 Oct 12.

7.

In Vitro Evaluation of Molecular Tumor Targets in Nuclear Medicine: Immunohistochemistry Is One Option, but Under Which Conditions?

Reubi JC.

J Nucl Med. 2017 Dec;58(12):1885-1887. doi: 10.2967/jnumed.117.197582. Epub 2017 Sep 14.

8.

Approaches to Multireceptor Targeting: Hybrid Radioligands, Radioligand Cocktails, and Sequential Radioligand Applications.

Reubi JC, Maecke HR.

J Nucl Med. 2017 Sep;58(Suppl 2):10S-16S. doi: 10.2967/jnumed.116.186882. Review.

9.

A Critical Evaluation of sst3 and sst5 Immunohistochemistry in Human Pituitary Adenomas.

Körner M, Waser B, Christ E, Beck J, Reubi JC.

Neuroendocrinology. 2018;106(2):116-127. doi: 10.1159/000472563. Epub 2017 Apr 7.

PMID:
28384628
10.

PET/CT Imaging of Unstable Carotid Plaque with 68Ga-Labeled Somatostatin Receptor Ligand.

Wan MYS, Endozo R, Michopoulou S, Shortman R, Rodriguez-Justo M, Menezes L, Yusuf S, Richards T, Wild D, Waser B, Reubi JC, Groves A.

J Nucl Med. 2017 May;58(5):774-780. doi: 10.2967/jnumed.116.181438. Epub 2016 Dec 8.

11.

Approaches to improve metabolic stability of a statine-based GRP receptor antagonist.

Popp I, Del Pozzo L, Waser B, Reubi JC, Meyer PT, Maecke HR, Gourni E.

Nucl Med Biol. 2017 Feb;45:22-29. doi: 10.1016/j.nucmedbio.2016.11.004. Epub 2016 Nov 4.

PMID:
27865999
12.

Highly Increased 125I-JR11 Antagonist Binding In Vitro Reveals Novel Indications for sst2 Targeting in Human Cancers.

Reubi JC, Waser B, Mäcke H, Rivier J.

J Nucl Med. 2017 Feb;58(2):300-306. doi: 10.2967/jnumed.116.177733. Epub 2016 Aug 25.

13.

Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers.

Rylova SN, Waser B, Del Pozzo L, Tönnesmann R, Mansi R, Meyer PT, Reubi JC, Maecke HR.

J Nucl Med. 2016 Aug;57(8):1282-8. doi: 10.2967/jnumed.115.168948. Epub 2016 Apr 28.

14.

Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer.

Gourni E, Del Pozzo L, Kheirallah E, Smerling C, Waser B, Reubi JC, Paterson BM, Donnelly PS, Meyer PT, Maecke HR.

Mol Pharm. 2015 Aug 3;12(8):2781-90. doi: 10.1021/mp500671j. Epub 2015 Jul 15.

PMID:
26132879
15.

Preoperative localization of adult nesidioblastosis using ⁶⁸Ga-DOTA-exendin-4-PET/CT.

Christ E, Wild D, Antwi K, Waser B, Fani M, Schwanda S, Heye T, Schmid C, Baer HU, Perren A, Reubi JC.

Endocrine. 2015 Dec;50(3):821-3. doi: 10.1007/s12020-015-0633-7. Epub 2015 May 23. No abstract available.

PMID:
26001537
16.

Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study.

Antwi K, Fani M, Nicolas G, Rottenburger C, Heye T, Reubi JC, Gloor B, Christ E, Wild D.

J Nucl Med. 2015 Jul;56(7):1075-8. doi: 10.2967/jnumed.115.157768. Epub 2015 May 21.

17.

Stereochemistry of amino acid spacers determines the pharmacokinetics of (111)In-DOTA-minigastrin analogues for targeting the CCK2/gastrin receptor.

Kolenc Peitl P, Tamma M, Kroselj M, Braun F, Waser B, Reubi JC, Sollner Dolenc M, Maecke HR, Mansi R.

Bioconjug Chem. 2015 Jun 17;26(6):1113-9. doi: 10.1021/acs.bioconjchem.5b00187. Epub 2015 May 20.

PMID:
25971921
18.

Neurotensin receptors in pancreatic ductal carcinomas.

Körner M, Waser B, Strobel O, Büchler M, Reubi JC.

EJNMMI Res. 2015 Mar 24;5:17. doi: 10.1186/s13550-015-0094-2. eCollection 2015.

19.

Triple-peptide receptor targeting in vitro allows detection of all tested gut and bronchial NETs.

Reubi JC, Waser B.

J Nucl Med. 2015 Apr;56(4):613-5. doi: 10.2967/jnumed.114.153189. Epub 2015 Feb 19.

20.

Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors?

Körner M, Waser B, Reubi JC.

Neuroendocrinology. 2015;101(1):45-57. doi: 10.1159/000371804. Epub 2015 Jan 12.

21.

Evaluation of three different families of bombesin receptor radioantagonists for targeted imaging and therapy of gastrin releasing peptide receptor (GRP-R) positive tumors.

Mansi R, Abiraj K, Wang X, Tamma ML, Gourni E, Cescato R, Berndt S, Reubi JC, Maecke HR.

J Med Chem. 2015 Jan 22;58(2):682-91. doi: 10.1021/jm5012066. Epub 2014 Dec 17.

PMID:
25474596
22.

Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas.

Waser B, Blank A, Karamitopoulou E, Perren A, Reubi JC.

Mod Pathol. 2015 Mar;28(3):391-402. doi: 10.1038/modpathol.2014.113. Epub 2014 Sep 12.

23.

N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.

Gourni E, Mansi R, Jamous M, Waser B, Smerling C, Burian A, Buchegger F, Reubi JC, Maecke HR.

J Nucl Med. 2014 Oct;55(10):1719-25. doi: 10.2967/jnumed.114.141242. Epub 2014 Aug 21.

24.

[111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors.

Maina T, Cescato R, Waser B, Tatsi A, Kaloudi A, Krenning EP, de Jong M, Nock BA, Reubi JC.

J Med Chem. 2014 Aug 14;57(15):6564-71. doi: 10.1021/jm500581d. Epub 2014 Jul 23.

PMID:
25007399
25.

Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study.

Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, Fischer R, Rivier JE, Reubi JC, Maecke HR, Weber WA.

J Nucl Med. 2014 Aug;55(8):1248-52. doi: 10.2967/jnumed.114.138834. Epub 2014 Jun 24.

26.

Strict rules are needed for validation of G-protein-coupled receptor immunohistochemical studies in human tissues.

Reubi JC.

Endocrine. 2014 Dec;47(3):659-61. doi: 10.1007/s12020-014-0320-0. Epub 2014 Jun 10. No abstract available.

PMID:
24913418
27.

PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonists.

Jamous M, Tamma ML, Gourni E, Waser B, Reubi JC, Maecke HR, Mansi R.

Nucl Med Biol. 2014 Jul;41(6):464-70. doi: 10.1016/j.nucmedbio.2014.03.014. Epub 2014 Mar 29.

PMID:
24780298
28.

The glucose-dependent insulinotropic polypeptide receptor: a novel target for neuroendocrine tumor imaging—first preclinical studies.

Gourni E, Waser B, Clerc P, Fourmy D, Reubi JC, Maecke HR.

J Nucl Med. 2014 Jun;55(6):976-82. doi: 10.2967/jnumed.113.133744. Epub 2014 Apr 17.

29.

Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.

Christ E, Wild D, Ederer S, Béhé M, Nicolas G, Caplin ME, Brändle M, Clerici T, Fischli S, Stettler C, Ell PJ, Seufert J, Gloor B, Perren A, Reubi JC, Forrer F.

Lancet Diabetes Endocrinol. 2013 Oct;1(2):115-22. doi: 10.1016/S2213-8587(13)70049-4. Epub 2013 Jul 25.

30.

Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men.

Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, Maecke HR, Reubi JC, Weber WA.

Theranostics. 2014 Feb 1;4(4):412-9. doi: 10.7150/thno.7324. eCollection 2014.

31.

Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors.

Wicki A, Wild D, Prêtre V, Mansi R, Orleth A, Reubi JC, Rochlitz C, Mamot C, Mäcke HR, Christofori G.

EJNMMI Res. 2014 Feb 16;4(1):9. doi: 10.1186/2191-219X-4-9.

32.

Radiolabelled GLP-1 receptor antagonist binds to GLP-1 receptor-expressing human tissues.

Waser B, Reubi JC.

Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1166-71. doi: 10.1007/s00259-013-2684-4. Epub 2014 Feb 12.

PMID:
24519555
33.

[DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting.

Tatsi A, Maina T, Cescato R, Waser B, Krenning EP, de Jong M, Cordopatis P, Reubi JC, Nock BA.

Eur J Med Chem. 2014 Feb 12;73:30-7. doi: 10.1016/j.ejmech.2013.12.003. Epub 2013 Dec 16.

PMID:
24378707
34.

Syntheses, receptor bindings, in vitro and in vivo stabilities and biodistributions of DOTA-neurotensin(8-13) derivatives containing β-amino acid residues - a lesson about the importance of animal experiments.

Sparr C, Purkayastha N, Yoshinari T, Seebach D, Maschauer S, Prante O, Hübner H, Gmeiner P, Kolesinska B, Cescato R, Waser B, Reubi JC.

Chem Biodivers. 2013 Dec;10(12):2101-21. doi: 10.1002/cbdv.201300331.

PMID:
24327436
35.

Illuminating somatostatin analog action at neuroendocrine tumor receptors.

Reubi JC, Schonbrunn A.

Trends Pharmacol Sci. 2013 Dec;34(12):676-88. doi: 10.1016/j.tips.2013.10.001. Epub 2013 Oct 31. Review.

36.

Early over-expression of GRP receptors in prostatic carcinogenesis.

Körner M, Waser B, Rehmann R, Reubi JC.

Prostate. 2014 Feb;74(2):217-24. doi: 10.1002/pros.22743. Epub 2013 Oct 22.

PMID:
24150752
37.

64Cu- and 68Ga-labelled [Nle(14),Lys(40)(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell imaging in rats.

Mikkola K, Yim CB, Fagerholm V, Ishizu T, Elomaa VV, Rajander J, Jurttila J, Saanijoki T, Tolvanen T, Tirri M, Gourni E, Béhé M, Gotthardt M, Reubi JC, Mäcke H, Roivainen A, Solin O, Nuutila P.

Mol Imaging Biol. 2014 Apr;16(2):255-63. doi: 10.1007/s11307-013-0691-2. Erratum in: Mol Imaging Biol. 2014 Apr;16(2):293. multiple author names corrected.

PMID:
24101374
38.

Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma.

Komor J, Reubi JC, Christ ER.

Pituitary. 2014 Jun;17(3):227-31. doi: 10.1007/s11102-013-0494-0.

PMID:
23740146
39.

Targeting GRPR in urological cancers--from basic research to clinical application.

Mansi R, Fleischmann A, Mäcke HR, Reubi JC.

Nat Rev Urol. 2013 Apr;10(4):235-44. doi: 10.1038/nrurol.2013.42. Epub 2013 Mar 19. Review.

PMID:
23507930
40.

Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin.

Dumont RA, Tamma M, Braun F, Borkowski S, Reubi JC, Maecke H, Weber WA, Mansi R.

J Nucl Med. 2013 May;54(5):762-9. doi: 10.2967/jnumed.112.112169. Epub 2013 Mar 14.

41.

Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.

Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME.

J Nucl Med. 2013 Mar;54(3):364-72. doi: 10.2967/jnumed.112.111724. Epub 2013 Jan 7.

42.

Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications.

Körner M, Christ E, Wild D, Reubi JC.

Front Endocrinol (Lausanne). 2012 Dec 6;3:158. doi: 10.3389/fendo.2012.00158. eCollection 2012.

43.

Evolution of bombesin conjugates for targeted PET imaging of tumors.

Zhang H, Abiraj K, Thorek DL, Waser B, Smith-Jones PM, Honer M, Reubi JC, Maecke HR.

PLoS One. 2012;7(9):e44046. Epub 2012 Sep 14.

44.

[(99m)Tc]Demomedin C, a radioligand based on human gastrin releasing peptide(18-27): synthesis and preclinical evaluation in gastrin releasing peptide receptor-expressing models.

Nock BA, Cescato R, Ketani E, Waser B, Reubi JC, Maina T.

J Med Chem. 2012 Oct 11;55(19):8364-74. doi: 10.1021/jm300741f. Epub 2012 Sep 26.

PMID:
22966957
45.

GLP-2 receptors in human disease: high expression in gastrointestinal stromal tumors and Crohn's disease.

Körner M, Rehmann R, Reubi JC.

Mol Cell Endocrinol. 2012 Nov 25;364(1-2):46-53. doi: 10.1016/j.mce.2012.08.008. Epub 2012 Aug 19.

PMID:
22951144
46.

Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy.

Wang X, Fani M, Schulz S, Rivier J, Reubi JC, Maecke HR.

Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1876-85. doi: 10.1007/s00259-012-2231-8. Epub 2012 Aug 29.

PMID:
22926735
47.

Old and new peptide receptor targets in cancer: future directions.

Reubi JC.

Recent Results Cancer Res. 2013;194:567-76. doi: 10.1007/978-3-642-27994-2_34.

PMID:
22918784
48.

A rare case of a large spinal meningioma with mediastinal extension and malignant behavior classified histologically as benign.

Dahdal S, Andres RH, Hewer E, Reubi JC, Klaeser B, Raabe A, Cihoric N, Schmid R, Tänzler K, Krause T, Aebersold DM, Schmuecking M.

Recent Results Cancer Res. 2013;194:443-55. doi: 10.1007/978-3-642-27994-2_24.

PMID:
22918774
49.

Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications.

Fani M, Braun F, Waser B, Beetschen K, Cescato R, Erchegyi J, Rivier JE, Weber WA, Maecke HR, Reubi JC.

J Nucl Med. 2012 Sep;53(9):1481-9. doi: 10.2967/jnumed.112.102764. Epub 2012 Jul 31.

50.

Secretin receptor promotes the proliferation of endocrine tumor cells via the PI3K/AKT pathway.

Lee M, Waser B, Reubi JC, Pellegata NS.

Mol Endocrinol. 2012 Aug;26(8):1394-405. doi: 10.1210/me.2012-1055. Epub 2012 Jun 12.

Supplemental Content

Loading ...
Support Center